Phase 3 Recruiting Academic/Other
This phase III trial compares cetuximab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer that may have spread from where it first started to nea…
Sponsor: NRG Oncology
NCT ID: NCT07441681
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
+ 147 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Locations: - Ironwood Cancer and Research Center — Chandler, Arizona
- University of Arizona Cancer Center — Tucson, Arizona
- Providence St Jude Medical Center — Fullerton, California
+ 48 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum…
Sponsor: Corbus Pharmaceuticals Inc.
NCT ID: NCT07768189
Locations: - Clearview Cancer Institute — Huntsville, Alabama
- The University of Arizona Cancer Center — Tucson, Arizona
- City of Hope Comprehensive Cancer Center — Duarte, California
+ 35 more sites in the U.S.
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Locations: - University of Alabama- Birmingham ( Site 5015) — Birmingham, Alabama
- Alaska Womens Cancer Care ( Site 5046) — Anchorage, Alaska
- CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5037) — Irvine, California
+ 31 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …
Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- The University of Arizona Cancer Center — Tucson, Arizona
- University of California Los Angeles — Los Angeles, California
+ 25 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Sit…
Sponsor: Privo Technologies
NCT ID: NCT05893888
Locations: - City of Hope National Medical Center — Duarte, California
- Miami Cancer Institute — Miami, Florida
- The University of Chicago — Chicago, Illinois
+ 1 more site in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary site) to othe…
Sponsor: Mayo Clinic
NCT ID: NCT06915727
Locations: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 2, Phase 3 Recruiting NIH
Background: People have 4 parathyroid glands near the thyroid gland in the neck. Surgery is needed to remove a parathyroid gland that is too large or has a tumor. These glands can be in different places, so doctors use an imaging scan with…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT ID: NCT07444723
Locations: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 676 more sites in the U.S.
Phase 2 Recruiting NIH
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Locations: - Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
+ 112 more sites in the U.S.
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Locations: - Local Institution - 2129 — Duarte, California
- Local Institution - 2120 — Glendale, California
- Local Institution - 2136 — La Jolla, California
+ 46 more sites in the U.S.
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Locations: - City of Hope — Duarte, California
- Oncura Health — Glendale, California
- UC San Diego Health - Moores Cancer Center — La Jolla, California
+ 36 more sites in the U.S.